Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational studyFRONTIERS IN PSYCHIATRYIF3.22023-12-044OAAI
Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early-and adult-onset patientsPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRYIF3.92022-03-019PRE
Treatment-resistant schizophrenia: differences in white matter integrity, intracortical glutamate levels, clinical, and cognitive measures between early- and adult-onset patientsEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010PRE
Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19-related traumaEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72021-12-010OAAI
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis阿立哌唑长效注射液治疗首发精神分裂症的探索性分析FRONTIERS IN PSYCHIATRYIF3.22020-01-0818OAAI
Aripiprazole long-acting injection in first psychotic episode managementEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72019-01-010PREAI
The problem of overcontrol: Perfectionism, emotional inhibition, and personality disordersCOMPREHENSIVE PSYCHIATRYIF4.22018-05-0146OAAI
Aripiprazole LAI vs. paliperidone LAI in inpatients with psychosis comorbid with substance use disorder: clinical and QoL effects at 1-year follow-upEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
Efficacy, safety, and tolerability of vortioxetine in the treatment of mood disordersEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
Heritable vulnerability in the early psychiatric onset and addictive behaviors: the role of temperamentEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向